Christopher Posner Net Worth

The estimated Net Worth of Christopher Posner is at least $774 Thousand dollars as of 1 August 2024. Mr. Posner owns over 4,149 units of Cara Therapeutics Inc stock worth over $50,006 and over the last 6 years he sold CARA stock worth over $421,807. In addition, he makes $302,024 as Independent Director at Cara Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Posner CARA stock SEC Form 4 insiders trading

Christopher has made over 14 trades of the Cara Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,149 units of CARA stock worth $1,452 on 1 August 2024.

The largest trade he's ever made was selling 35,575 units of Cara Therapeutics Inc stock on 8 February 2024 worth over $18,855. On average, Christopher trades about 4,870 units every 68 days since 2018. As of 1 August 2024 he still owns at least 172,436 units of Cara Therapeutics Inc stock.

You can see the complete history of Mr. Posner stock trades at the bottom of the page.

Christopher Posner biography

Christopher Posner serves as Independent Director of the Company. Mr. Posner has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. Since July 2017, he has been the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University. Mr. Posner’s extensive experience in the pharmaceutical industry, including in commercial and marketing operations, provides him with the qualifications to serve on the Board.

What is the salary of Christopher Posner?

As the Independent Director of Cara Therapeutics Inc, the total compensation of Christopher Posner at Cara Therapeutics Inc is $302,024. There are 11 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.

How old is Christopher Posner?

Christopher Posner is 50, he's been the Independent Director of Cara Therapeutics Inc since 2018. There are 12 older and 5 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.

What's Christopher Posner's mailing address?

Christopher's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 400 ATLANTIC STREET, SUITE 500, STAMFORD, CT, 06901.

Insiders trading at Cara Therapeutics Inc

Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.

What does Cara Therapeutics Inc do?

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Complete history of Mr. Posner stock trades at Cara Therapeutics Inc

Cara Therapeutics Inc executives and stock owners

Cara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joana Goncalves,
  Chief Medical Officer
• Derek Chalmers,
  President, Chief Executive Officer, Director
• Frederique Menzaghi,
  Senior Vice President, Research and Development, Chief Scientific Officer
• Scott Terrillion,
  Chief Compliance Officer, General Counsel, Secretary
• Dr. Derek T. Chalmers D.Sc., Ph.D.,
  Co-Founder & Sr. Advisor
• Dr. Frédérique Menzaghi,
  Chief Scientific Officer and Sr. VP of R&D
• Dr. Joana Goncalves,
  Chief Medical Officer
• Scott M. Terrillion,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Richard Makara,
  VP, Head of Accounting, Controller & Principal Accounting Officer
• Martin Vogelbaum,
  Lead Independent Director
• Harrison Bains,
  Independent Director
• Christopher Posner,
  Independent Director
• Jeffrey Ives,
  Independent Director
• Thomas Charles Reilly,
  Chief Financial Officer
• Christopher A. Posner,
  Pres, CEO & Director
• Susan Shiff,
  Director
• Richard Makara,
  Vice President, Head of Accounting & Controller
• Thomas Reilly,
  Chief Financial Officer
• Eric Vandal,
  Sr. VP of Commercial
• Dr. Michael E. Lewis Ph.D.,
  Co-Founder & Chief Scientific Advisor
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Josef Schoell,
  Chief Financial Officer
• Dean Slagel,
  Director
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Michael E Lewis,
  Chief Scientific Advisor
• Joseph William Stauffer,
  Chief Medical Officer
• Robert Medve,
  Chief Medical Officer
• Ventures Vi Lp Rho Capital ...,
  
• Charles Ph.D. Moller,
  Director
• Biopharma Partners Iii Lpal...,
  
• Edward Hurwitz,
  Director
• Ryan D Maynard,
  CHIEF FINANCIAL OFFICER
• Moltke Lisa Von,
  
• Helen M Boudreau,